Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert - 2Why ordering takeout or calling the dog walker might lead to a happier relationship
- 3Landslides triggered by heavy rainfall kill at least 20 people in Tanzania
- 4Vote In favor of Your Number one Savvy Beds
- 5EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- Taylor Swift just released the 'Elizabeth Taylor' music video — but she's not the star of it
- German politician urges more face-to-face interaction in digital age
- Savvy Tips for Seniors Hyundai IONIQ EV
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
- Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- Kristin Cavallari was the teen queen bee of 'Laguna Beach.' Now she's a 'cringey' mom.
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
